Literature DB >> 2062847

CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients.

V Ghetie1, C Slaughter, H T Wheeler, J W Uhr, E S Vitetta.   

Abstract

Sera from human immunodeficiency virus-positive (HIV+; Walter Reed stage 6) individuals inhibit the interaction between recombinant human CD4 and recombinant gp120 from HIV (rCD4 and rgp120, respectively), thereby interfering with the ability of soluble rCD4 to block infection with HIV or rCD4-toxin conjugates to kill HIV-infected cells. In this report we demonstrate that the inhibitory activity of such sera is caused primarily by anti-gp120 antibodies that do not recognize the CD4 interaction site on gp120. To circumvent the problem of inhibition, we have generated a construct containing a peptide of CD4 (residues 41-84) conjugated to ovalbumin (three to five peptides per molecule). This multivalent conjugate binds to rgp120 and binding is not inhibited by antibodies in HIV+ sera.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2062847      PMCID: PMC51943          DOI: 10.1073/pnas.88.13.5690

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Tissue sulfhydryl groups.

Authors:  G L ELLMAN
Journal:  Arch Biochem Biophys       Date:  1959-05       Impact factor: 4.013

2.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

Authors:  L A Lasky; G Nakamura; D H Smith; C Fennie; C Shimasaki; E Patzer; P Berman; T Gregory; D J Capon
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

3.  Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity.

Authors:  J D Lifson; K M Hwang; P L Nara; B Fraser; M Padgett; N M Dunlop; L E Eiden
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

Review 4.  Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining.

Authors:  E Ishikawa; M Imagawa; S Hashida; S Yoshitake; Y Hamaguchi; T Ueno
Journal:  J Immunoassay       Date:  1983

5.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

6.  Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.

Authors:  V K Chaudhary; T Mizukami; T R Fuerst; D J FitzGerald; B Moss; I Pastan; E A Berger
Journal:  Nature       Date:  1988-09-22       Impact factor: 49.962

7.  HIV-infected cells are killed by rCD4-ricin A chain.

Authors:  M A Till; V Ghetie; T Gregory; E J Patzer; J P Porter; J W Uhr; D J Capon; E S Vitetta
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

8.  Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding.

Authors:  S M Schnittman; H C Lane; J Roth; A Burrows; T M Folks; J H Kehrl; S Koenig; P Berman; A S Fauci
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

9.  Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.

Authors:  P S Linsley; J A Ledbetter; E Kinney-Thomas; S L Hu
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

10.  A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus.

Authors:  R A Ezekowitz; M Kuhlman; J E Groopman; R A Byrn
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  1 in total

1.  Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus.

Authors:  K D Bell; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.